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Abstract 21 
Objectives:  22 
Proton pump inhibitors (PPIs) are commonly prescribed for prevention and treatment of 23 
gastrointestinal conditions or for gastroprotection from other drugs.  Research suggests they are 24 
linked to increased dementia risk. We use linked national health data to examine the association 25 
between PPI use and the development of incident dementia.  26 
Methods and findings: 27 
A population-based study using electronic health-data from the Secure Anonymised Information 28 
Linkage (SAIL) Databank, Wales (UK) from 1999 to 2015. Of data available on 3,765,744 individuals, a 29 
cohort who had ever been prescribed a PPI was developed (n=183,968) for people aged 55 years and 30 
over and compared to non-PPI exposed individuals (131,110). Those with prior dementia, mild-31 
cognitive-impairment or delirium codes were excluded. Confounding factors included comorbidities 32 
and/or drugs associated with them. Comorbidities might include head injury and some examples of 33 
medications include antidepressants, antiplatelets and anticoagulants. These commonly prescribed 34 
drugs were investigated as it was not feasible to explore all drugs in this study. The main outcome 35 
was a diagnosis of incident dementia. Cox proportional hazard regression modelling was used to 36 
calculate the Hazard ratio (HR) of developing dementia in PPI-exposed compared to unexposed 37 
individuals while controlling for potential confounders.  38 
The mean age of the PPI exposed individuals was 69.9 years and 39.8% male while the mean age of 39 
the unexposed individuals was 72.1 years and 41.1% male. The rate of PPI usage was 58.4% 40 
(183,968) and incident dementia rate was 11.8% (37,148/315,078). PPI use was associated with 41 
decreased dementia risk (HR: 0.67, 95% CI: 0.65 to 0.67, p<0.01).   42 
Conclusions:  43 
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This study, using large-scale, multi-centre health-data was unable to confirm an association between 44 
PPI use and increased dementia risk.  Previously reported links may be associated with confounders 45 
of people using PPI’s, such as increased risk of cardiovascular disease and/or depression and their 46 
associated medications which may be responsible for any increased risk of developing dementia.  47 
Key words: Dementia, Proton pump inhibitors (PPIs). 48 
  49 
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Introduction 50 
Proton pump inhibitors (PPIs) have revolutionised the management of stomach acid suppression, 51 
successfully managing patients with gastro-oesophageal reflux disease (GORD). They effectively 52 
resolve GORD symptoms in 60-80% of patients within 1-2 months (1)  and their use is on the rise 53 
(2,3). Long-term PPI use may also be a prophylactic measure and serve as a gastro-protectant for 54 
concomitant medications such as aspirin, well known to irritate the digestive tract (4,5). 55 
However, evidence suggests that PPIs are overprescribed (6) and inappropriately prescribed (7,8). 56 
With increased prescription, particularly through Europe (9); their cost to the National Health Service 57 
in the UK  is more than £100 million each year (10).   58 
Some of the safety concerns associated with long-term use of PPIs include: cancer (11,12) masking 59 
symptoms of other underlying conditions (13), infections (14–18), celiac disease (19), vitamin-B12 60 
deficiency (20), abnormal kidney function (21,22), and more recently, dementia (23,24). The 61 
association between PPI and dementia is potentially mediated by a PPI-induced increase of the 62 
protein amyloid-beta that contributes to the pathophysiology of dementia (25,26), or vitamin-B12 63 
deficiency caused by malabsorption induced by PPIs (27). 64 
It was recently reported that PPI medications were associated with an almost two-fold (44%) 65 
increased risk of developing dementia (23), causing wide-spread concern over their safety. The 66 
findings were highlighted by the media with little mention of methodological limitations. These 67 
limitations include: the study design with a selected population sourced from German health 68 
insurance data claims; a control group with significant differences from the PPI exposed group; and 69 
increased comorbidities. Comorbidities such as ischaemic heart disease and depression are risk 70 
factors for developing dementia. These could result in residual confounding, contributing to an 71 
increased incidence of dementia in PPI exposed individuals in previous studies (23). A subsequent 72 
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study, using German primary care data found that PPIs were actually associated with a decreased 73 
risk of dementia (28). However, a meta-analysis published in 2016 showed an increase risk of 74 
dementia with PPI use, but only four observational studies could be included and heterogeneity and 75 
methodological shortcomings were highlighted (29).  76 
Another study suggested that PPIs do not increase the risk of dementia or cognitive impairment and 77 
were associated with an approximate 20% risk reduction.  This investigation relied on self-reporting 78 
of PPI use, which may result in misclassification and recall bias, especially if individuals had memory 79 
issues (30). Other studies were also unable to find an association of PPI usage and cognitive 80 
impairment or dementia (31–34) including a case-control study which took the PPI duration of 81 
exposure in to account (35). 82 
There are clearly challenges in evaluating the safety of PPIs (36) with studies reporting contradictory 83 
findings of an increased risk of dementia (23,24,29) or no associated risk (28,30–32,35).  84 
We examine a vast source of linked, routinely collected health-data while correcting for known 85 
confounders to examine the relationship between PPI and dementia risk. We used a cohort study so 86 
that we could directly compare our findings to existing publications.  87 
 88 
Methods 89 
Routinely collected data 90 
Data were obtained from the Secure Anonymised Information Linkage (SAIL) databank (37,38) that 91 
allows the linkage of routine clinical records. These include primary care and mortality data collected 92 
by the Office of National Statistics (ONS). The SAIL databank houses multi-sourced records from 5 93 
million of the living and deceased population of Wales. The records are anonymised using a split-file 94 
6 
 
approach; the demographic and clinical data are divided and sent to a third party where a unique 95 
linking field is applied - removing any identifiers. This allows the files to be recombined later. We are 96 
then able to, retrospectively and prospectively, follow-up individuals anonymously through different 97 
data sources.  Previous work using the SAIL databank to investigate PPIs has been published 98 
elsewhere (39). 99 
Primary care data is captured using Read codes relating to diagnoses, medication and process-of-100 
care codes (40). The Office of National Statistics (ONS) Mortality dataset contains demographic, 101 
place and underlying cause of death data using the International Classification of Diseases (ICD) 102 
clinical coding system.   103 
Data was included from December 1999 to September 2015 for optimum data coverage purposes at 104 
the time of analysis.  105 
Individuals who had ever taken PPIs were those with Read code records for prescriptions of PPI 106 
medications. They were followed-up and compared to non-PPI exposed individuals. The individuals 107 
first PPI prescription date formed the index date for the PPI exposed group.  A random index date 108 
within the follow-up period was used for the control population who did not receive a PPI. This 109 
avoided pre-selecting a period of known ill-health for controls. In addition, using a true event date 110 
could bias the control population to more active healthcare users, due to their visitation to the 111 
doctor and may be less generalisable as a result. Individuals of 55 years age or above were included 112 
due to the increased risk of gastrointestinal complaints with advancing age (41).  113 
Of the 3,765,744 individuals in the SAIL databank who were aged 55 years or older, 1,043,040 had 114 
records of PPI use compared to 2,722,704 who did not. Individuals were excluded when they had 115 
less than one year of data available in their records from the index date and/or had records of 116 
dementia, mild cognitive impairment or delirium prior to the index date (Fig 1). 117 
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Primary outcome 118 
The primary outcome was dementia Read codes present in the primary care data post index date.  119 
The list of codes used for dementia classification is available in S1 Table. These codes have been 120 
previously validated for use in UK epidemiological studies (42).  Data was linked to ONS data to 121 
obtain mortality data. 122 
Covariates of interest and confounding factors 123 
The covariates were extracted at baseline from routine primary care data using the READ Code 124 
clinical coding system or derived data where appropriate. These included personal characteristics 125 
(age, sex, smoking status, obesity and alcohol consumption). The confounding comorbidities 126 
(diabetes, cardiovascular disease, depression, anxiety, head injury, hypertension, high cholesterol, 127 
vitamin-B12 deficiency and anaemia) and concomitant medications (anxiolytics, anti-depressants, 128 
anticoagulants, antiplatelets, statins, hormone replacement therapy (HRT), vitamin-B12 supplements, 129 
iron and antihypertensives) were extracted throughout the patient record; prior to or post- index 130 
date (S2 Table). The rationale to include these confounders during the study period was to adjust for 131 
known factors that may occur in the long follow-up period. For instance, an extreme event such as a 132 
head injury or a long-term health condition, such as cardiovascular disease, which may occur in 133 
either PPI exposed or non-exposed group post-index date and these have been adjusted for in the 134 
model.  135 
Statistical analysis 136 
Descriptive statistics were used to examine age, gender and covariate distribution for the 137 
participants of the cohort. 138 
A step-wise cox proportional hazard regression model was employed to calculate hazard ratios while 139 
controlling for covariates and potential confounding factors. Univariate analysis (S3 Table) 140 
determined factors to be included in the multivariate model. Censoring occurred when a patient 141 
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died, was lost to follow-up (i.e. moved out of Wales resulting in incomplete health-records) or 142 
reaching the end of the study period (records up to 2015 at time of analysis).  143 
Sensitivity analysis was performed, excluding patients who were taking vitamin-B12 which may help 144 
prevent cognitive decline (43).  145 
Additionally, associations of developing dementia and the duration from first treatment with PPI 146 
were assessed in a sensitivity analysis comprising individuals who developed dementia within 2 147 
years, 5 years and 10 years of index date compared to those who had not received PPIs.  148 
Missing data were treated as missing throughout the study. All statistical analyses were conducted 149 
using STATA15. 150 
Ethical approval  151 
Data held in the SAIL databank are anonymised and therefore, no ethical approval is required. All 152 
data contained in SAIL has the permission from the relevant Caldicott Guardian or Data Protection 153 
Officer. SAIL-related projects are required to obtain Information Governance Review Panel (IGRP) 154 
approval. 155 
 156 
Results 157 
Patient characteristics  158 
The population consisted of 315,078 individuals, 40.3% were male (127184/315078) and the mean 159 
age was 70.8 years. The mean follow-up time for the whole cohort was 13.04 years (SD: 4.95). The 160 
proportion of PPI usage was 58.4% (183,968) and the incident dementia was 11.8% 161 
(37,148/315,078).  162 
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The PPI exposed group was slightly younger on average by 2.2 years. The proportion of females was 163 
slightly higher in the PPI exposed group (60.2%) compared to the unexposed group (58.9%) (Table 1). 164 
Within the PPI exposed group, the incidence of dementia was 11.4% (21,023) and 12.3% (16,125) for 165 
the unexposed. The mean age at dementia diagnosis was similar in the PPI and non-PPI exposed 166 
groups; 82.1 years and 81.5 years, respectively (Table 1). 167 
The mean follow-up time for PPI and non-PPI exposed was 10.9 years (SD: 4.0) and 8.6 years (SD: 168 
4.4), respectively. The rate of death was significantly higher in the non-PPI (53.3%) exposed group 169 
compared to the PPI exposed group (43.5%) (Difference: 9.8, 95% CI: 9.5 to 10.2). The age of death 170 
was similar for both groups however the PPI group was slightly older (PPI: 85 years and non-PPI: 84.3 171 
years) (Table 1). 172 
The characteristics of the study populations are presented in Table 1 and S3 Table.  173 
Table 1. Characteristics of PPI exposed and unexposed patients at baseline 174 
 PPI 
n= 183,968 
No PPI 
n= 131,110 
Difference 
(95% CI) 
Age˄, mean years (SD) 69.9  (70) 72.1 (7.6) 2.2 (1.8 to 2.6) 
Female, % (n) 60.2%  (110,720) 58.9% (77,174) 1.3 (1.0 to 1.7) 
BMI˄, mean (SD) 26.3  (5.1) 25.8 (5.1) 0.5 (0.5 to 0.5) 
Drink alcohol˄, % (n) 3% (5,510) 2.3% (2,977) 0.7 (0.6 to 0.8) 
Smoker† % (n)  20.4% (36,320) 29.9% (37,290) 9.5 (9.2 to 9.8) 
Dementia % (n) 11.4% (21,023) 12.3% (16,125) 0.9 (0.6 to 1.1) 
Age at  dementia diagnosis, mean 
years (SD) 
 
82.1  (6.7) 81.5 (6.8) 0.6 (0.5 to 0.7) 
Diabetes† % (n) 19.4% (35,778) 14.6% (19,132) 4.8 (4.6 to 5.1) 
Cardiovascular disease† % (n) 53.9% (99,065) 38% (49,768) 15.9 (15.5 to 16.2) 
Depression† % (n) 32.7% (60,167) 20.1% (26,404) 12.6 (12.3 to 12.9) 
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˄ Covariates collected at index date 175 
† Covariates collected throughout patient history, pre- or post- index date 176 
Missing data for PPI exposed: 36.7% for BMI (n=67,569) and 3.3% (n=6,057) for smoking status.  177 
Missing data for non-exposed: 47.4% for BMI (n=62,118) and 4.9% (n=6,444) for smoking status.  178 
 179 
PPI and dementia 180 
PPIs were not associated with an increased risk of dementia. Rather, PPI usage was associated with 181 
around a 30% reduced risk (Adjusted HR: 0.67, 95% CI: 0.65 to 0.69, p<0.001) (Tables 2 & 3); (Crude 182 
HR: 0.82, 95% CI: 0.80 to 0.84) (S3 Table).  183 
Table 2:  Adjusted Hazard ratio of developing dementia when taking a PPI 184 
compared to a control population using a retrospective cohort. 185 
Head injury† % (n) 6.4% (11,739) 4.8%  (6,315) 1.6 (1.4 to 1.7) 
Vitamin B12 deficiency† % (n) 0.8%  (1,516) 0.6%  (734) 0.2 (0.2 to 0.3) 
Anaemia† % (n) 19.1% (35,153) 9.7% (12,739) 9.4 (9.2 to 9.6) 
Anxiolytics† % (n) 29.1% (53,434) 16.8% (22,044) 12.3 (11.9 to 12.5) 
Antidepressants† % (n) 50.1%  (92,235) 28.9% (37,847) 21.2 (20.9 to 21.6) 
Anticoagulants† % (n) 20.7% (38,002) 14.7% (19,257) 6 (5.7 to 6.2) 
Antiplatelets† % (n) 66.7% (122,632) 47.2% (61,838) 19.5 (19.2 to 19.8) 
Statins †% (n) 59.5% (109,444) 36.9% (48,343) 22.6 (22.3 to 23) 
Hormone replacement therapy† % 
(n) 
9.9% (18,274) 4.3% 
(5,617) 
5.6 
(5.5 to 5.8) 
Vitamin B12 medication† % (n) 5.7% (10,421) 3.4% (4,506) 2.3 (2.1 to 2.4) 
Anaemia medication† % (n) 38.6% (71,047) 19% (24,933) 19.6 (19.3 to 19.9) 
Antihypertensives† % (n) 71.6% (131,740) 54.1% (70,925) 17.5 (17.2 to 17.9) 
H2-receptor antagonists† % (n) 19.1% (35,203) 6.1% (7,935) 13 (12.9 to 13) 
Died % (n) 43.5 % (79,974) 53.3% (69,917) 9.8 (9.5 to 10.2) 
Mean age died, years (SD) 85 (6.0) 84.3 (5.8) 0.7 (0.6 to 0.8) 
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  Hazard ratio 95% CI 
PPI  0.67  0.65 to 0.69* 
Adjusted for:   
Age 1.06 1.05 to 1.06* 
Smoker 0.89 0.85 to 0.92* 
BMI 0.95 0.95 to 0.95* 
Diabetes 1.18 1.14 to 1.22* 
Cardiovascular disease 0.93 0.90 to 0.97* 
Depression 1.19 1.16 to 1.23* 
Head injury 1.50 1.43 to 1.56* 
Vitamin-B12 Deficiency  1.37 1.21 to 1.56* 
Anxiolytics 1.62 1.57 to 1.67* 
Antidepressants 1.66 1.61 to 1.72* 
Anticoagulants 0.87 0.84 to 0.89* 
Antiplatelets 1.72 1.66 to 1.79* 
Statins 0.86 0.85 to 0.94* 
Hormone replacement therapy 0.89  0.85 to 0.94* 
Vitamin-B12 Medication 1.41 1.34 to 1.48* 
Anaemia Medication 1.10 1.06 to 1.13* 
Antihypertensives 0.71 0.69 to 0.74* 
Histamine Receptor-2 Medication 0.89 0.85 to 0.94* 
*P < 0.05 186 
Gender, Anaemia and alcohol use were included in the model, but removed as did not reach 187 
statistical significance. 188 
 189 
Sensitivity analysis 190 
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A sensitivity analysis of removing vitamin B-12 deficiency from the model did not alter the results for 191 
the cohort study (S4 Table).  192 
To test the assumption that PPI initiation may predispose individuals to dementia, in a sensitivity 193 
analysis we investigated subgroups of individuals who were diagnosed with dementia following 2 194 
years, 5 years and 10 years of first mention of PPI treatment. This demonstrated that when 195 
excluding individuals with varying exposures to PPIs, the hazard ratio of developing dementia 196 
reduced in the PPI exposed patients compared to the non-exposed and furthermore, as the time 197 
period increased (S3 Table).198 
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Table 3:  Sensitivity analysis: Adjusted hazard ratios of developing dementia for varying time points following PPI Index 199 
date compared to unexposed controls. 200 
 Whole cohort 
Including all dementia 
cases (n= 37,148) 
Including dementia cases 
(n=13,484) diagnosed 2 
years or more post-index 
date 
 
36% of all dementia cases 
Including dementia  
cases (n=9,822) 
diagnosed 5 years or 
more post-index date 
 
26.4% of all dementia cases 
 
Including dementia cases 
(n=4,594) diagnosed 10 
years or more post-index 
date 
 
12.4% of all dementia cases 
  HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
PPI 67 0.65 to 0.69* 0.58 0.56 to 0.60* 0.46 0.46 to 0.48* 0.29 0.28 to 0.30* 
Age 1.05 1.05 to 1.06* 1.05 1.05 to 1.06* 1.06 1.05 to 1.06* 1.06 1.06 to 1.06* 
Drink alcohol 1.10 1.01 to 1.18* 1.20 1.13 to 1.28* 1.18 1.10 to 1.25* 1.15 1.07 to 1.24* 
Smoker 0.89 0.85 to 0.92* 0.89 0.86 to 0.92* 0.90 0.87 to 0.94* 0.91 0.87 to 0.95* 
BMI 0.95 0.95 to 0.95* 0.95 0.95 to 0.95* 0.95 0.95 to 0.95* 0.95 0.95 to 0.95* 
Diabetes 1.18 1.14 to 1.22* 1.18 1.14 to 1.23* 1.18 1.14 to 1.22* 1.18 1.13 to 1.23* 
Cardiovascular disease 0.93 0.90 to 0.97* 0.94 0.91 to 0.98* 0.95 0.92 to 0.98* 0.95 0.92 to 0.99* 
Depression 1.19 1.16 to 1.23* 1.19 1.15 to 1.24* 1.20 1.15 to 1.24* 1.17 1.12 to 1.21* 
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Head injury 1.49 1.43 to 1.56* 1.50 1.43 to 1.57* 1.51 1.43 to 1.59* 1.53 1.44 to 1.62* 
Vitamin-B12 Deficiency  1.37 1.21 to 1.56* 1.42 1.25 to 1.61* 1.41 1.23 to 1.62* 1.44 1.23 to 1.69* 
Anxiolytics 1.62 1.57 to 1.67* 1.65 1.60 to 1.70* 1.69 1.63 to 1.74* 1.77 1.70 to 1.84* 
Antidepressants 1.66 1.61 to 1.72* 1.68 1.62 to 1.74* 1.68 1.61 to 1.74* 1.70 1.63 to 1.78* 
Anticoagulants 0.87 0.84 to 0.91* 0.88 0.85 to 0.92* 0.88 0.84 to 0.92* 0.89 0.84 to 0.93* 
Antiplatelets 1.72 1.66 to 1.79* 1.72 1.66 to 1.79* 1.73 1.66 to 1.80* 1.70 1.63 to 1.78* 
Statins 0.86 0.83 to 0.89* 0.86 0.83 to 0.94* 0.87 0.83 to 0.90* 0.85 0.82 to 0.89* 
Hormone replacement therapy 0.89  0.83 to 0.89* 0.89 0.84 to 0.94* 0.91 0.86 to 0.96* 0.96 0.90 to 1.02 
Vitamin-B12 Medication 1.37 1.34 to 1.48* 1.44 1.37 to 1.52* 1.44 1.36 to 1.53* 1.46 1.36 to 1.56* 
Anaemia Medication 1.09 1.06 to 1.13* 1.10 1.07 to 1.14* 1.11 1.07 to 1.15* 1.12 1.07 to 1.16* 
Antihypertensives 0.71 0.69 to 0.73* 0.71 0.69 to 0.74* 0.71 0.68 to 0.73* 0.69 0.66 to 0.72* 
Histamine Receptor-2 Medication 0.91 0.88 to 0.95* 0.97 0.93 to 1.01 1.04 1.0 to 1.09* 1.01 1.03 to 1.06* 
*P < 0.05 201 
Note: 9,248 (24.9%) dementia cases were removed from this analysis as they developed dementia within two years of the PPI date.  Gender, Anaemia 202 
and alcohol use were included in the model, but removed as did not reach statistical significance. 203 
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Discussion 204 
This study does not find evidence that PPI use is associated with an increased risk of dementia. 205 
Rather, in support for Booker et al., and Goldstein et al., our study, using large-scale, multi-sourced 206 
health-data, found that PPI usage was associated with a 30% lower risk of dementia. Our findings 207 
originate from data collected in a real-world setting which provided a heterogeneous sample, 208 
thereby overcoming selection bias which may have been an issue in previous studies.  209 
The PPI exposed and non-exposed groups were slightly different. Those who were not treated with 210 
PPIs tended to be slightly older, smoked more and had less comorbidities and concomitant 211 
medications recorded in their routine health records compared to the PPI exposed group. There was 212 
also higher rate of death in the non-PPI exposed group compared to the PPI exposed. This may 213 
suggest that patients who are treated with PPIs are more closely monitored and are higher 214 
healthcare resource users; whereas patients who do not receive PPIs may visit their GP less overall.  215 
When adjusted for covariates, some were associated with an increased risk of dementia (e.g. 216 
increasing age, head injury and depression). Other factors were associated with a reduced risk of 217 
dementia, including a lower BMI and cardiovascular disease. However, cardiovascular disease is an 218 
established risk factor for developing dementia (44). Our findings may be explained by the increased 219 
risk of death in those who have serious comorbidities, meaning that they are at greater risk of dying 220 
earlier, before getting dementia. 221 
However, some findings were interesting, for instance anticoagulants were associated with a lower 222 
risk of dementia in this study, while those taking antiplatelets developed dementia much earlier. 223 
However, this must be explored in additional study since this study was designed to explore risk of 224 
dementia with PPI usage.    225 
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It is important to consider that it is not known how long dementia takes to develop and how long the 226 
latent stages may last. Dementia may also not be diagnosed until later stages in the disease or on 227 
the other hand, may remain undiagnosed (45–47). 228 
Therefore, by conducting sensitivity analysis omitting patients who were recently diagnosed with 229 
dementia following PPI treatment we could help to address the effects of misclassification bias. For 230 
instance, those who were diagnosed with dementia within one year of PPI treatment initiation 231 
would have been experiencing the early symptoms of dementia for some time already. These were 232 
existing dementia cases who would have been administered PPIs during the prodromal stage and so 233 
were misclassified. Patients who were diagnosed with dementia at 5 years and 10 years post-234 
treatment initiation intervals also demonstrated an association of reduced incidence in dementia 235 
adding further support to the notion that PPIs are not associated with developing dementia.  236 
However, competing interest of death may also be an implication, which is often an issue with 237 
ageing cohorts. Nevertheless, no increased risk of dementia was associated with PPI usage in this 238 
study. 239 
Strengths 240 
To our knowledge, this study involves the analysis of the largest-to-date follow-up of PPI and 241 
dementia cases from routinely collected health-records with up to 16 years average follow-up time. 242 
This allowed the assessment in a real-life setting which helps avoid selection bias and improve 243 
generalisability. Using routinely collected health-records for research purposes means that events 244 
are captured as they occur in the patient record rather than self-reported. Therefore, co-conditions, 245 
medications and head injuries for instance are confirmed in the data which overcomes recall bias in 246 
self-reported studies. 247 
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The use of a cohort study is also advantageous over a case-control design when using retrospective 248 
database studies, where all exposure and covariate data is already available. A case-control 249 
approach may result in inappropriate comparisons between exposure groups and lead to 250 
confounding (48). Dementia can be a very slow developing condition however the long follow-up in 251 
this study meant that prodromal dementia could be followed until diagnosis. Dementia is also a 252 
complex, multifactorial condition and known potential confounders have been included in our 253 
analysis to help to reduce residual confounding, however this can never be assumed to be complete. 254 
Weaknesses 255 
While routinely collected health-records are advantageous in their use for secondary research 256 
purposes, they may also have their disadvantages, such as missing data. This study does not take in 257 
to account the duration or dose of PPI treatment, however this has been investigated elsewhere and 258 
long-term use was not associated with an increased risk of developing AD (35). Also, some PPIs are 259 
also available to purchase over-the-counter and so, we are unable to control for this within this 260 
study. Furthermore, a prescription for PPIs in the primary healthcare record does not necessarily 261 
guarantee that the individual has taken the medication which can lead to misclassification bias.  262 
Pre-symptomatic dementia cases may also have been misclassified to the control population 263 
however this may be addressed by the time-lag sensitivity analysis.  264 
We did not stratify on dementia type so that our findings were  comparable to previous studies 265 
(23,24,28). However, our future work will explore risk factors of developing dementia by dementia 266 
sub-type.   267 
Given the advancing age of the cohort, the competing risk of death (49) is likely to be high which was 268 
not controlled for in this study.  The rate of death was higher in the PPI unexposed group, however 269 
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the age of death was similar for both groups and was beyond the mean age of dementia diagnosis. A 270 
weakness of the cox proportional hazard is that the risk of disease may be overestimated by failing 271 
to control for competing risk of death (49,50). As such, the hazard ratio may be slightly over-272 
estimated, which in this instance, adds further support to the lack of association of PPI treatment 273 
with dementia in this cohort.   274 
Finally, the rate of alcohol use was considerably low in the routine data. This may suggest that the 275 
rate of reporting alcohol was indeed low, had not been recorded well in primary care or be 276 
associated with the fact that the cohort was older and rate of drinking alcohol was truly low. 277 
To conclude, our evidence suggests that PPIs are not associated with an increased risk of dementia. 278 
Rather, there is a 30% reduced risk associated with the widely prescribed gastro-protectants. 279 
Mechanisms behind potential protective effects of PPIs include anti-neurotoxic effects, such as 280 
reduction of brain oxidative stress and reduced neutrophil infiltration or inflammation in the brain 281 
(51,52). 282 
Further research in to the relationship between PPIs and a reduced risk of dementia, such as 283 
stratifying on the type of dementia can help us understand more about PPIs and their interactions 284 
during the pathogenesis of distinct dementias. Medications associated with a lower risk of dementia 285 
can be explored further, with regard to dose and duration of treatment for different dementias. 286 
Enhanced understanding of the associations between different medications and dementia not only 287 
supports greater understanding of the disease process itself, but can also earmark existing therapies 288 
to be investigated further as potential agents to be repurposed to target dementia. 289 
This study finds no evidence for concern about developing dementia after taking a PPI. This may 290 
reassure people who are currently taking them, however due to the limitations of this study further 291 
research is needed, for instance, to ascertain the effect of duration of PPI exposure.  292 
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